Anebulo Pharmaceuticals, Inc. (ANEB)
| Market Cap | 161.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.46M |
| Shares Out | 13.61M |
| EPS (ttm) | -2.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,580 |
| Open | 7.03 |
| Previous Close | 6.99 |
| Day's Range | 6.90 - 7.03 |
| 52-Week Range | 6.31 - 9.33 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 15, 2021 |
About ANEB
Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. There is no approved medical treatment currently available to specifically alleviate the symptoms of cannabinoid ov...
News
Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabi...
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...
Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
Photo by Elsa Olofsson on Unsplash Many people today remain unaware of the risks an overdose of marijuana carries. In fact, some people don't believe overdosing on cannabis to be possible.
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its financial results Wednesday for the three and 12 months ended June 30. Over the fourth quarter of fiscal 202...
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxicati...
Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxicati...
Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...
A Week's Worth of Actionable Cannabis Stock News
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up...
Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...
Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) released its third-quarter fiscal 2021 financial results on Tuesday with a net loss of $555,832 or $0.04 per share. The ...
Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Res...
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...
Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...
Rain Therapeutics headlines newest slate of IPO-bound biotechs with $100M penciled in for lead oncology program
A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.
Anebulo Pharmaceuticals IPO Registration Document (S-1)
Anebulo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.